TalkPoint and partner for series of FDA public workshops

Share Article

Workshop will discuss minimal residual disease (MRD) as a possible response in group of hematological malignancies

News Image

TalkPoint, the industry leader in global communications technology, specializing in browser-based audio and video webcasting, and (, the leading provider of live video webcasts of the Food and Drug Administration (FDA) Advisory Committee meetings, today announced it is partnership for a series of FDA workshops. The next workshop “Public Workshop on Minimal Residual Disease (MRD)” will establish the processes and procedures necessary to qualify a prognostic biomarker, MRD, as a possible response or efficacy biomarker in a group of hematological malignancies.

The workshop, using TalkPoint’s webcasting technology, will be held on February 27 and March 4 from 8 a.m. to 4 p.m. ET. During the workshop, The Office of Hematology and Oncology Products plans to explore the potential utility of MRD as a surrogate endpoint in acute lymphoblastic leukemia (ALL) (including the relapsed setting), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

To register for the webcast and for information on upcoming events, please visit

About TalkPoint

TalkPoint is the industry leader in global communications technology, specializing in browser-based audio and video webcasting. Since 1998, TalkPoint's easy-to-use, Software-as-a-Service (SaaS) cloud platform has facilitated more than 20,000 live webcasting events per year for the top Fortune 500 and FTSE 100 companies. From investor relations and corporate communications to product launches and continuing education, TalkPoint offers scalable and flexible technology to meet today's business communication needs. For more information, visit

About ( provides live video webcasts of FDA Advisory Committee meetings captured on location. These meetings cover an array of topics related to medicinal health including OTC, prescription and treatment devices. These meetings often result in rulings on clinical trials, final approval and bans of medications and treatment options. TalkPoint is the exclusive webcast provider for

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lindsay Rolfson
Visit website